These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16868875)

  • 21. [Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Schute LL
    Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1448; author reply 1448. PubMed ID: 15213879
    [No Abstract]   [Full Text] [Related]  

  • 22. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
    Gialama F; Maniadakis N
    Vasc Health Risk Manag; 2013; 9():575-92. PubMed ID: 24124375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
    Coyle D; Rodby RA
    Can J Cardiol; 2004 Jan; 20(1):71-9. PubMed ID: 14968145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic challenges in the management of diabetic nephropathy.
    Rodby RA
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S6-11. PubMed ID: 15369419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.
    Ravera M; Re M; Vettoretti S
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S44-8. PubMed ID: 16565246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
    Delea TE; Sofrygin O; Palmer JL; Lau H; Munk VC; Sung J; Charney A; Parving HH; Sullivan SD
    J Am Soc Nephrol; 2009 Oct; 20(10):2205-13. PubMed ID: 19762496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
    Ravera M; Ratto E; Vettoretti S; Parodi D; Deferrari G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S48-52. PubMed ID: 15938034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
    Belousov IuB; Shestakova MV; Belousov DIu
    Kardiologiia; 2008; 48(12):14-9. PubMed ID: 19076089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.